References
- Pazdur R, Wagman LD, Camphausen KA, Hoskins JA. Cancer management: a multidisciplinary approach. New Delhi: CBS Publisher and Distributor; 2009:91–8
- Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1999;14:21–34
- Verma RK, Kaur J, Kumar K, et al. Intracellular time course pharmacokinetics and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother 2008;52:3195–201
- Budzynska R, Nevozhay D, Kanska U, et al. Antitumor activity of mannan-methotrexate conjugated in vitro and in vivo. Oncol Res 2007;16:415–21
- Nag A, Ghosh RC. Assessment of targeting potential of galactosylated and mannosylated sterically stabilized liposomes to different cell types of mouse liver. J Drug Target 1999;6:427–38
- Jain A, Agarwal A, Majumder S, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Rel 2010;148:359–67
- Shaji J, Jain V. Solid lipid nanoparticles: a novel carrier for chemotherapy. Int J Pharm 2010;2:8–17
- Lim SJ, Lee MK, Kim CK. Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders. J Control Rel 2004;100:53–61
- Bisht S, Maitra A. Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. Adv Rev 2000;91:415–25
- Li R, Eun JS, Lee MK. Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration. Arch Pharm Res 2011;34:331–7
- Zhang YL, Zhang ZH, Jiang TY, et al. Cell uptake of paclitaxel solid lipid nanoparticles modified by cell-penetrating peptides in A549 cells. Die Pharmazie 2013;68:47–53
- Yao HJ, Ju RJ, Wang XX, et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancer by oral delivery. Biomaterials 2011;32:3285–302
- Schubert MA, Muller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles evaluation of the method and process parameters. Eur J Pharm Biopharm 2003;55:125–31
- Jain AK, Jain SK. Development and characterization of nanolipobeads based dual drug delivery system for H. Pylori targeting. J Drug Targ 2013;21:593–603
- Utreja S, Jain NK. Solid lipid nanoparticles. In: Jain NK, ed. Advances in controlled and novel drug delivery. New Delhi: CBS Publishers and Distributors; 2001:408–24
- Fry DW, White JC, Goldman ID. Rapid separation of low molecular weight solute from liposomes without dilution. Anal Biochem 1978;890:809–15
- Bocca C, Caputo O, Cavalli R, et al. Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int J Pharm 1998;175:185–93
- Vanicha V, Kanyawim K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature Protocol 2006;1:1112–16
- Papazisis KT, Geromichalos GD, Kortsaris KA, Dimitriadis AH. Optimization of the sulforhodamine B colorimetric assay. J Immunol Meth 1997; 208:151–8
- Duncan R, Bhakoo M, Riley ML, Tuboku-Metzger A. Soluble polymeric drug carriers haematocompatibility. In: Gomez-Fernandez JC, Chapman D, eds. Progress in membrane biotechnology. Birkhauser: Verlag Basel; 1991:121–9
- Bhadra D, Bhadra S, Jain S, Jain NK. PEGylated dendritic nanoparticulate carrier of 5-fluorouracil. Int J Pharm 2003;257:111–24
- Reddy LH, Murthy RSR. Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Paper 2004;148:161–6